A Clinical Trial of Rimegepant for Vestibular Migraine Evaluation: Pre-experiment

Exclusion Criteria

• •Pregnant women, lactating women, or reluctance to use approved contraception during study participation;
• •There is a condition or abnormality that the investigator believes will affect the safety of the patients or the quality of the data;
• •Allergic to the ingredients of Remeipine sulfate or sulfate;
• •Previous treatment with remejepam;
• •History of ear surgery (except for ear tube surgery);
• •Other vestibular diagnoses (excluding treated benign paroxysmal positional vertigo BPPV). Including Meniere's disease, superior semicircular canal prolapse syndrome, vestibular neuritis, persistent postural perceptual vertigo, unilateral or bilateral loss of vestibular function, cerebellar or brainstem disease, multiple sclerosis or sea sickness;
• •Failure of more than 2 preventive migraine drugs;
• •Previous or current treatment with CGRP drugs;
• •History of serious medical or mental illness (including significant coronary artery disease, peripheral vascular disease, cerebrovascular disease, kidney disease, liver disease, Raynaud's disease, uncontrollable mental illness, or past psychiatric hospitalization, at the discretion of the treating physician);
• •A history of mania, psychosis, or suicidal ideation;
• •Acceptable if no more than two drugs for migraine prevention (prescribed specifically for this purpose) are used and the dose has stabilized for 2 months before the start of the study;
• •History of drug or alcohol abuse based on the subject's medical record or self-reported report within 12 months before the screening period;
• •Bototoxin (e. g., Dysport®, ®, Xeomin®, Myobloc®, and JeuveauTM) for the head, face, or neck during the study.